• CEO, Dr James Garner presents a review of FY19 and look ahead at the Kazia 2019 AGM read more

Kazia is a new company, with great potential in its pipeline, a clear strategy to realise value for shareholders, and a lean team with the experience and expertise to deliver benefit to patients.

 

  • News

    ..

    More News

  • Events

    20 - 24 November 2019

    Society of NeuroOncology (SNO) 2019 Annual Meeting

    Kazia is attending the Society of NeuroOncology (SNO) 2019 Annual Meeting in Phoenix, Arizona on 20-24 November 2019. 

    Kazia representatives, and Prof Patrick Wen of the Dana-Farber Cancer Institute, will be presenting interim data, via a poster, from our ongoing Phase II study of GDC-0084 in glioblastoma. Click here for more details.

    Professor Ben Ellingson, Director of the UCLA Brain Tumor Imaging Laboratory has been invited to give an oral presentation to SNO on a retrospective analysis of the Phase I study of GDC-0084 in recurrent glioma, which was completed by Genentech. Click here for more details.

    10 - 11 December 2019

    Glioblastoma Drug Development Summit, Boston MA 10 and 11 December 2019

    Dr James Garner is presenting at this inaugural event on the topic of “Realising potential: Taking GDC-0084 forward in Glioblastoma”. Click here for more details. 

    13 - 15 January 2020

    JP Morgan Healthcare Week

    Dr James Garner is presenting at Biotech Showcase, part of JP Morgan Healthcare Week, 13-15 January 2020 in San Francisco, California. Click here for more details.

    More Events

  • Resources

    5-SEP-2019

    Edison Research - GDC-0084 gets a fifth collaboration

    23-JUN-2019

    Edison Research - Higher MTD, new collaboration for GDC-0084

    31-Oct-2018

    Edison Research - New indications for GDC-0084

    24-Sep-2018

    Edison Research - GDC-0084 and Cantrixil trials progressing

  • Share Price

    Historical Prices